ATOS
Atossa Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.71 / 10
Netural
Fund flow analysis reveals a positive bias (7.41/10) with net inflows across block, small, medium, large, and extra-large categories, despite an overall negative trend in some patterns. Analyst coverage is limited to one institution but is uniformly bullish (Strong Buy). This combination of robust fund inflows and bullish analyst stance provides a supportive backdrop against the weak technicals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-08
InstitutionAscendiant Capital
Times predicted4
Historical Win Rate50.0%
What is the analyst consensus for ATOS?
- ATOS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.71/10 (Netural).
